MedTrace Logo

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

NCT05918406 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-06

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray

Conditions

  • Dry Eye
  • Keratoconjunctivitis Sicca

Interventions

COMBINATION_PRODUCT

Nasal Guide

Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID

Sponsors & Collaborators

  • Oyster Point Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Marian Macsai, MD · Oyster Point Pharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-14
Primary Completion
2023-08-18
Completion
2023-08-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918406 on ClinicalTrials.gov